Bicistronic CAR T-cell therapy can produce durable complete responses in pediatric patients with relapsed or refractory B-ALL, data suggest.
The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy to treat unresectable or metastatic, HER2-, PD-L1+ gastric or GEJ adenocarcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback